John M. Pagel
Acting Instructor, University of Washington, Department of Medicine, Division of Oncology, 2005.
Associate in Clinical Research, Fred Hutchinson Cancer Research Center, 2002.
Senior Fellow, Fred Hutchinson Cancer Research Center, Department of Medicine, Division of Oncology, 1999.
Internal Medicine Residency, University of California, San Francisco, Department of Medicine, 1999.
Internal Medicine Internship, University of California, San Francisco, Department of Medicine, 1997.
M.D., Magna cum laude, Boston University, School of Medicine, 1996.
Post-doctoral, University of California, San Francisco, Howard Hughes Research Associate, 1992.
Ph.D., University of California, Irvine, Microbiology and Molecular Genetics, 1991.
Dr. Pagel leads leukemia studies of radioimmunotherapy at the Center as the principal investigator of several human clinical trials. He is working to increase the usefulness of antibody therapy by "pretargeting" radiation directly to the cells. He is also researching nonradioactive chemical partners to antibodies.
American Society for Blood and Marrow Transplantation
American Society of Hematology
European Association of Nuclear Medicine
Puget Sound Oncology Consortium
Honors and Awards
2005, Clinical Investigator Award, Damon Runyon Cancer Research Foundation
2004, Career Development Award, Lymphoma Research Foundation
2004, Career Development Award, ASCO
2002, Young Investigator Award, ASCO
1994, Pathology Honor Society, Assoc. of Pathology Chairs, BU School of Medicine
1994, Alpha Omega Alpha Medical Honor Society, BU School of Medicine
1993, Family Medicine Interest Gr. Leadership Award, Am. Academy of Family Physicians
1991-1992, Howard Hughes Post-doctoral Research Award, UCSF
1988-1991, National Institutes of Health Pre-doctoral Fellow, UC Irvine
1986, Univ. of California Undergraduate Research Award, UC Riverside
1985, University of California Presidents Award, UC Riverside
1982, Bank of America Academic Leadership Award, UCLA
1982-1986, Mountains Community Hospital Health Profession Scholarship, UCLA
1982, University of California Chancellor's Scholarship, UCLA
1982-1983, Ralph J. Bunche Academic Scholarship, UCLA
131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.. Nuclear medicine communications. 33(12):1225-31.. 2012.
Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.. British journal of haematology. 155(2):182-9.. 2011.
Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(10):1537-45.. 2011.
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(9):1190-7.. 2011.
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(3):341-50.. 2011.
Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(6):908-15.. 2011.
Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 17(23):7373-82.. 2011.
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(22):3023-9.. 2011.
HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(10):1382-7.. 2010.
Recent advances in novel radioimmunotherapeutic approaches for allogeneic hematopoietic cell transplantation.. Current opinion in oncology. 22(2):143-9.. 2010.
Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.. Bioconjugate chemistry. 21(7):1225-38.. 2010.
Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 24(7):1276-82.. 2010.
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignan. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(8):1037-69.. 2010.
Pretargeted radioimmunotherapy for hematologic and other malignancies.. Cancer biotherapy & radiopharmaceuticals. 25(2):125-42.. 2010.